Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
Trial details
- Registry ID
- NCT04082364
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
Also recorded as Onivyde / Leucovorin (LV) / Fluorouracil (5-FU)
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerNCT04082364 | MacroGenics | Phase 2, Phase 3 | Completed | 2024-01-15Actual |
| Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer PatientsNCT02826486 | BLRX | Phase 2 | Completed | 2022-09-06Actual |
| CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLCNCT04495153 | CADL | Phase 2 | Active not recruiting | 2024-12-31Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |